Nabilone Use for Acute Pain in Inflammatory Bowel Disease Patients With Chronic Opioid Use Undergoing Gastrointestinal Surgery: A Single-centered Randomized Controlled Trial

This is a clinical trial of nabilone for patients with Inflammatory Bowel Disease (IBD) who are undergoing IBD-related surgery (Any abdominal surgery lasting for more than one hour). This study would include a total of 80 patients undergoing general surgery who will have Intravenous Patient Controlled Analgesia (IVPCA) after surgery. It is the intention to randomize these patients postoperatively into 2 groups of 40 patients:
1. Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and nabilone as per protocol.
2. Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and placebo as per protocol.
The goal is two-fold. One is to demonstrate that patients will benefit from post-operative nabilone administration to achieve/maintain the opioid-sparing and pain modulation effects. Second is to demonstrate patients will benefit from the anti-inflammatory and immunomodulatory effects of nabilone to alleviate IBD symptoms and enhance recovery.

开始日期2023-12-01

申办/合作机构

Samuel Lunenfeld Research Institute

NCT05885685

/ Completed临床4期IIT

Investigating the Effects of Nabilone on Endocannabinoid Metabolism in the Human Brain

The purpose of this study is to learn about the effects of a cannabis-like substance, nabilone, on the levels of endocannabinoid enzyme fatty acid amide hydrolase (FAAH) in brain of healthy individuals. Using magnetic resonance imagine (MRI) and positron emission tomography (PET), the main questions we aim to answer are: 1) Does nabilone decrease levels of FAAH in the brain? and 2) Are changes in levels of FAAH associated with clinical response to nabilone? Participants will complete:
* An in-person interview (
4 hours)
* Two brain imaging scanning sessions (
11 hours)
* A one week 2 mg titrated dose of nabilone
* Virtual check-ins (up to
1.5 hours)

开始日期2023-10-31

申办/合作机构

Centre for Addiction & Mental Health

NCT05742698

/ Recruiting临床2期IIT

Double Blind Crossover Clinical Trial of Nabilone for Agitation in Frontotemporal Dementia

The primary goal of this study is to test the hypothesis that oral nabilone treatment will reduce agitation compared with placebo in patients with Frontotemporal Dementia (both behavioural variant frontotemporal dementia and primary progressive aphasia). The study population is defined as patients with probable Frontotemporal Dementia that meet the International Psychogeriatric Association criteria for agitation in cognitive disorders.

开始日期2023-03-07

申办/合作机构

Douglas Mental Health University Institute

[+1]

100 项与大麻隆相关的临床结果

登录后查看更多信息

100 项与大麻隆相关的转化医学

登录后查看更多信息

100 项与大麻隆相关的专利（医药）

登录后查看更多信息

382

项与大麻隆相关的文献（医药）

2026-02-01·ANNALS OF INTERNAL MEDICINE

Cannabis-Based Products for Chronic Pain

Review

作者: Fu, Rongwei ; Chou, Roger ; Ahmed, Azrah Y. ; Morasco, Benjamin J.

BACKGROUND:

Benefits and harms of cannabinoids for chronic pain are uncertain.

PURPOSE:

To update an evidence synthesis on cannabinoids for chronic pain.

DATA SOURCES:

Ovid MEDLINE, PsycINFO, Embase, the Cochrane Library, and Scopus to 28 July 2025.

STUDY SELECTION:

Randomized placebo-controlled trials.

DATA EXTRACTION:

Data extraction, risk of bias, and strength of evidence were dually reviewed. Cannabinoids were categorized by tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratio (high, comparable, or low), source (synthetic, purified, extracted), and administration method.

DATA SYNTHESIS:

25 short-term (1 to 6 months) randomized controlled trials (n = 2303; 64% neuropathic pain) assessed cannabinoids. Oral synthetic/purified high THC-to-CBD (THC only) may slightly reduce and oromucosal, extracted, comparable THC-to-CBD ratio products probably slightly reduce pain severity (pooled differences, -0.78 and -0.54 points, respectively, [0 to 10 scale]), with moderate or large increased dizziness, sedation, and nausea. Among THC-only products, nabilone moderately reduced pain severity but dronabinol did not (pooled differences, -1.59 and -0.23 points, respectively). Low THC-to-CBD interventions may not improve outcomes. Although low THC-to-CBD mixed THC/CBD products may increase dizziness, sedation, and nausea, CBD alone may not increase harms.

LIMITATION:

Variability within categories; lack of product details; unclear U.S. availability of studied products; restricted to English-language studies.

CONCLUSION:

Comparable and high THC-to-CBD ratio cannabinoid products may result in small improvements in pain and increased common adverse events during short-term treatment of primarily neuropathic pain; among high-ratio THC-only products, nabilone (but not dronabinol) reduced pain. Low THC-to-CBD products may not improve outcomes. Studies are needed on long-term outcomes and other cannabis product types.

PRIMARY FUNDING SOURCE:

Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services (PROSPERO: CRD42021229579).

2026-01-27·JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Therapeutic Use of Cannabis and Cannabinoids

Review

作者: Gold, Mark S. ; Hsu, Michael ; Shah, Arya ; Hill, Kevin P. ; Jordan, Ayana

Importance:

Approximately 27% of adults in the US and Canada report having ever used cannabis for medical purposes. An estimated 10.5% of the US population reports using cannabidiol (CBD), a chemical compound extracted from cannabis that does not have psychoactive effects, for therapeutic purposes.

Observations:

Conditions for which cannabinoids have approval from the US Food and Drug Administration include HIV/AIDS–related anorexia, chemotherapy-induced nausea and vomiting, and certain pediatric seizure disorders. A meta-analysis of randomized clinical trials reported a small but significant reduction in nausea and vomiting from various causes (eg, chemotherapy, cancer) when comparing prescribed cannabinoids (eg, dronabinol, nabilone) with placebo or active comparators (eg, alizapride, chlorpromazine; standardized mean difference [SMD], −0.29 [95% CI, −0.39 to −0.18]). A meta-analysis of randomized clinical trials among patients with HIV/AIDS reported that cannabinoids had a moderate effect on increasing body weight compared with placebo (SMD, 0.57 [95% CI, 0.22 to 0.92]). Evidence-based guidelines do not recommend the use of inhaled or high-potency cannabis (≥10% or 10 mg Δ9-tetrahydrocannabinol [Δ9-THC]) for medical purposes. High-potency cannabis compared with low-potency cannabis use is associated with increased risk of psychotic symptoms (12.4% vs 7.1%) and generalized anxiety disorder (19.1% vs 11.6%). A meta-analysis of observational studies reported that 29% of individuals who used cannabis for medical purposes met criteria for cannabis use disorder. Daily inhaled cannabis use compared with nondaily use was associated with an increased risk of coronary heart disease (2.0% vs 0.9%), myocardial infarction (1.7% vs 1.3%), and stroke (2.6% vs 1.0%). Evidence from randomized clinical trials does not support the use of cannabis or cannabinoids for most conditions for which it is promoted, such as acute pain and insomnia. Before considering cannabis or cannabinoids for medical use, clinicians should consult applicable institutional, state, and national regulations; evaluate for drug-drug interactions; and assess for contraindications (eg, pregnancy) or conditions in which risks likely outweigh benefits (eg, schizophrenia or ischemic heart disease). For patients using cannabis or cannabinoids for treatment of medical conditions, clinicians should discuss harm reduction strategies, including avoiding concurrent use with alcohol or other central nervous system depressants such as benzodiazepines, using the lowest effective dose, and avoiding use when driving or operating machinery.

Conclusions and Relevance:

Evidence is insufficient for the use of cannabis or cannabinoids for most medical indications. Clear guidance from clinicians is essential to support safe, evidence-based decision-making. Clinicians should weigh benefits against risks when engaging patients in informed discussions about cannabis or cannabinoid use.

2026-01-01·INTERNATIONAL PSYCHOGERIATRICS

Assessment of clinical factors that predict response to nabilone for agitation in Alzheimer’s disease: A post hoc analysis of a randomized placebo-controlled trial

Article

作者: L G Verhoeff, Nicolaas Paul ; Herrmann, Nathan ; Black, Sandra E ; Gallagher, Damien ; Ruthirakuhan, Myuri ; Lanctôt, Krista L ; Feldman, Oriel J ; Kiss, Alex

INTRODUCTION:

Previously, nabilone showed a medium effect size for treating agitation in moderate-to-severe Alzheimer's disease (AD), but response varied. These post hoc analyses aimed to identify a group of clinical characteristics that predicted treatment response.

METHODS:

Data from a double-blind, placebo-controlled crossover trial in AD agitation were used. Nineteen clinical characteristics were categorized (presence/absence) and evaluated for relation to agitation response (change on Cohen-Mansfield Agitation Inventory (CMAI)). Characteristics with a ≥ 8 point response difference between categories were included in a multivariable analysis model to calculate individual predicted response. Linear mixed-effects models with Satterthwaite's approximation evaluated the impact of treatment on the relationship between predicted and observed responses.

RESULTS:

Thirty-nine participants (77 % male, mean [SD] age 87 [10.2], standardized Mini-Mental State Exam (sMMSE) 6.5 [6.8]) were enrolled. Variable selection identified five characteristics related to greater nabilone efficacy: higher pain (Pain Assessment in Advanced Dementia score ≥3) (difference [SE] in CMAI response = -18.8 [3.2]), greater appetite and eating disorders (-16.4 [5.5]), greater apathy (-14.0 [5.5]), less cognitive impairment (sMMSE greater than 10) (-16.5 [4.2]) and no concomitant cholinesterase inhibitors (-13.9 [4.4]). For those with a predicted response in the top tertile based on those five characteristics, 82 % responded, compared with 40 % in the lowest tertile. A treatment-by-tertile interaction (F(2,29) = 8.48, p = 0.001) indicated observed treatment response varied across tertiles.

CONCLUSION:

A reliable clinical profile of persons with AD related agitation likely to respond to nabilone may be established with additional research.

项与大麻隆相关的新闻（医药）

2026-01-29

·阿尔茨海默病研究

2021-2026年全球AD药物研发管线分析

AD_Drug_Development_2021-2026.xlsx 关键词：阿尔茨海默病、药物、临床、研发、Phase 25年的AD药物统计还没看到，AI先做了一个汇总表阿尔茨海默病(AD)药物研发汇总报告 2021-2026年全球AD药物研发管线分析数据摘要已上市药物 3个 (Lecanemab, Donanemab, Aduhelm[退市]) Phase 3在研 18个 Phase 2/3在研 8个 Phase 2在研 22个 Phase 1在研 10个研发失败/终止 19个总计 80个药物说明本报告汇总了2021-2026年间全球阿尔茨海默病药物研发情况，包括已上市药物、在研药物（Phase 1-3）以及研发失败的药物。数据来源于ClinicalTrials.gov、PubMed、FDA等权威机构。涵盖Aβ靶向、tau靶向、神经炎症、老药新用等多种机制。 23/24年大佬整理的药物研发情况汇总：参考文献 ClinicalTrials.gov https://clinicaltrials.gov PubMed https://pubmed.ncbi.nlm.nih.gov FDA https://www.fda.gov Alzheimer's & Dementia (Journal) https://alz-journals.onlinelibrary.wiley.com Nature Reviews Drug Discovery https://www.nature.com/nrd New England Journal of Medicine https://www.nejm.org JAMA Neurology https://jamanetwork.com/journals/jamaneurology Lancet Neurology https://www.thelancet.com/neurology Cummings et al. 2025 Pipeline Report Alzheimer's Dement 2025;11:e70098 Alzforum https://www.alzforum.org Alzheimers Dement (N Y). 2023 May 25;9(2):e12385. Alzheimers Dement (N Y). 2024 Apr 24;10(2):e12465. 本文内容来自公开信息及研究文献，不代表临床建议。如需投稿、转载、商务合作后台留言，回复有一定延迟敬请谅解。辅助编辑：腾讯元宝or（GPT、Gemini、Claude等）扫码加入ima知识库，获取本公众号所有文献全文资料，AI问答了解更多信息，文献实时更新药品名称进展阶段临床试验编号所属公司/机构开发起始时间备注 GV-971 (Sodium Oligomannate) 中国已上市/全球Phase 3终止 NCT04520412 (Green Memory) Green Valley Pharma (China) 2019 中国2019年批准，国际III期2022年终止 Lecanemab (Leqembi) 已上市 (FDA 2023.1加速批准, 2023.7完全批准) NCT03887455 (Clarity AD) Eisai / Biogen / BioArctic 2020 抗Aβ原纤维抗体，减缓认知下降27% Donanemab (Kisunla) 已上市 (FDA 2024.7批准) NCT04437511 (TRAILBLAZER-ALZ 2) Eli Lilly 2020.6 抗Aβ抗体，低/中tau患者减缓下降60% Remternetug Phase 3 (进行中) NCT05463731 (TRAILRUNNER-ALZ1) Eli Lilly 2022.8 第三代抗Aβ抗体，皮下/静脉给药 ALZ-801 (Valiltramiprosate) Phase 3 (进行中) NCT04770220 (APOLLOE4) Alzheon 2021.5 口服Aβ寡聚体抑制剂，针对APOE4/4纯合子 Semaglutide Phase 3 (进行中) NCT04777396 / NCT04777409 (EVOKE/EVOKE+) Novo Nordisk 2021.5 GLP-1受体激动剂，老药新用 Nilotinib Phase 3 (进行中) NCT05143528 Novartis 2022.2 酪氨酸激酶抑制剂，老药新用 Masitinib Phase 3 (进行中) NCT05564169 AB Science 2022 酪氨酸激酶抑制剂，抗炎 KarXT (Xanomeline-Trospium) Phase 3 (进行中) NCT05511363 Karuna Therapeutics / Bristol-Myers Squibb 2022 毒蕈碱受体激动剂组合 Masupirdine (SUVN-502) Phase 3 (进行中) NCT05397639 Suven Pharmaceuticals 2022 5-HT6受体拮抗剂，用于激越症状 Nabilone Phase 3 (进行中) NCT04516057 University of Toronto 2020 大麻素受体激动剂，老药新用，用于激越 Dextromethorphan/Quinidine Phase 3 (进行中) NCT03389922 Otsuka / Avanir 2018 用于AD相关激越 NE3107 Phase 3 (进行中) NCT04669028 BioVie 2021 口服抗炎胰岛素增敏剂 AR1001 Phase 3 (进行中) NCT05531526 AriBio 2022 PDE5抑制剂，老药新用 ATH-1017 (Fosgonimeton) Phase 3 (进行中) NCT04488419 Athira Pharma 2020 肝细胞生长因子增强剂 AXS-05 (Dextromethorphan/Bupropion) Phase 3 (进行中) NCT05526968 Axsome Therapeutics 2022 用于AD相关激越 Trontinemab (RO7126209) Phase 3 (进行中) NCT06385072 Roche / Genentech 2024 Brainshuttle技术抗Aβ抗体，基于gantenerumab ALZ-801 (Long-term Extension) Phase 3扩展 (进行中) NCT06304883 Alzheon 2023 APOLLOE4试验长期扩展 Blarcamesine (ANAVEX 2-73) Phase 2/3 (完成) NCT03790709 Anavex Life Sciences 2019 Sigma-1受体激动剂，已提交欧洲上市申请 Piromelatine Phase 2/3 (进行中) NCT05267535 Neurim Pharmaceuticals 2022.5 褪黑素受体激动剂 Buntanetap Phase 2/3 (进行中) NCT05686044 Annovis Bio 2023 神经毒性聚集蛋白翻译抑制剂 Metformin Phase 2/3 (进行中) NCT04098666 University of Pennsylvania 2021.3 降糖药，老药新用 E2814 (Etalanetug) Phase 2/3 (进行中) NCT05269394 (DIAN-TU Tau NexGen) Eisai / UCL 2022.1 抗tau抗体，靶向MTBR，获FDA快速通道资格 Rotigotine + Rivastigmine Phase 2/3 (进行中) NCT04185099 University of California 2019 多巴胺激动剂+胆碱酯酶抑制剂 Lecanemab + E2814 Phase 2/3 (进行中) NCT05269394 (DIAN-TU-001) Eisai 2022 抗Aβ+抗tau组合疗法 ABBV-916 Phase 2 (进行中) NCT05291234 AbbVie 2022 抗Aβ抗体，靶向N3pG-Aβ CT1812 (Zervimesine) Phase 2 (进行中) NCT03507790 (SHINE) / NCT05531656 (START) Cognition Therapeutics 2018 Sigma-2受体调节剂 Bepranemab (UCB0107) Phase 2 (进行中) NCT04867616 Roche / UCB 2021 抗tau抗体，靶向tau中央区域 JNJ-63733657 Phase 2 (进行中) NCT04619420 (AUTONOMY) Janssen 2020 抗tau抗体，靶向p-tau217 LY3372689 Phase 2 (进行中) NCT05063539 Eli Lilly 2021.9 O-GlcNAcase抑制剂，小分子 BIIB080 (IONIS-MAPTRx) Phase 2 (进行中) NCT05399888 (CELIA) Biogen / Ionis 2022 Tau反义寡核苷酸 ACI-35 Phase 2 (进行中) NCT04445831 AC Immune / Janssen 2020 抗tau疫苗 Hydralazine Hydrochloride Phase 2 (进行中) NCT04842552 University of Colorado 2021 老药新用，激活Nrf2通路 Caffeine Phase 2 (进行中) NCT04570085 University of Miami 2020 腺苷受体拮抗剂，老药新用 Sildenafil Phase 2 (进行中) NCT05403764 Cleveland Clinic 2022 PDE5抑制剂，老药新用 Dasatinib + Quercetin Phase 2 (进行中) NCT04063124 Mayo Clinic 2019 衰老细胞清除剂，老药新用 Liraglutide Phase 2 (进行中) NCT05653675 Novo Nordisk 2023 GLP-1受体激动剂，老药新用 Foralumab Phase 2 (进行中) NCT06382623 Tiziana Life Sciences 2024 抗CD3单抗，鼻内给药，针对神经炎症 PRX005 Phase 2 (进行中) NCT06126686 Prothena 2023 抗tau抗体 Exenatide Phase 2 (进行中) NCT04269349 University of Oxford 2020 GLP-1受体激动剂，老药新用 Lixisenatide Phase 2 (进行中) NCT05837287 Sanofi 2023 GLP-1受体激动剂，老药新用，帕金森病 Tirzepatide Phase 2 (进行中) NCT06556289 Eli Lilly 2024 GLP-1/GIP双受体激动剂，老药新用 Dulaglutide Phase 2 (进行中) NCT05844971 Eli Lilly 2023 GLP-1受体激动剂，老药新用 Tadalafil Phase 2 (进行中) NCT05422885 University of California 2022 PDE5抑制剂，老药新用 Vardenafil Phase 2 (进行中) NCT05575076 University of Pennsylvania 2022 PDE5抑制剂，老药新用 Ibudilast Phase 2 (进行中) NCT05549530 MediciNova 2022 PDE4/PDE3抑制剂，抗炎 Saracatinib Phase 2 (进行中) NCT05256052 AstraZeneca 2022 Src/Fyn激酶抑制剂 AZD0530 Phase 2 (进行中) NCT05256052 AstraZeneca 2022 Src激酶抑制剂 Posdinemab (ACI-35-028) Phase 2 (进行中) NCT06126686 AC Immune / Janssen 2023 抗磷酸化tau抗体 AADvac1 Phase 2完成 (未达主要终点) NCT04170891 (ADAMANT) Axon Neuroscience 2020 抗tau疫苗，未达主要终点 ASN51 Phase 2终止 (2025) NCT05544431 Asceneuron 2022 tau靶向药物，战略调整终止 Lu AF87908 Phase 1 (完成) NCT04149860 Lundbeck 2019 抗磷酸化tau抗体 PNT001 Phase 1 (完成) NCT05059380 Pinteon Therapeutics 2021 抗cis-pT231 tau抗体 MK-2214 Phase 1 (进行中) NCT05544431 Merck 2022 抗tau抗体 APNmAb005 Phase 1 (进行中) NCT05575076 Applied NeuroSolutions 2022 抗tau寡聚体抗体 Denali TVD (Transferrin Receptor) Phase 1 (进行中) NCT05712223 Denali Therapeutics 2023 脑穿梭技术平台，抗体递送 DNL919 Phase 1 (进行中) NCT05544431 Denali Therapeutics 2022 TREM2激活剂，脑穿梭技术 AL101 (GSK4527226) Phase 1 (进行中) NCT05575076 Alector / GSK 2022 Progranulin增强单抗 NI006 Phase 1 (进行中) NCT05575076 University Hospital Zurich 2022 抗Aβ纳米抗体 ATN-101 Phase 1 (进行中) NCT05575076 Aton Pharma 2022 抗Aβ抗体 RG7345 Phase 1终止 (2015) NCT01952637 Roche / Genentech 2015 抗tau抗体 BIIB076 Phase 1终止 (2022) NCT03113815 Biogen / Neurimmune 2017 抗tau抗体 AL002 Phase 2 (失败) NCT04592874 (INVOKE-2) Alector 2020 TREM2激动剂抗体，INVOKE-2试验未达终点 Ponezumab Phase 2失败 NCT00960531 Pfizer 2012 抗Aβ抗体 Gosuranemab (BIIB092) Phase 2失败 (2021终止) NCT03352557 Biogen / Bristol-Myers Squibb 2018 抗tau抗体，未达主要终点 Tilavonemab (ABBV-8E12) Phase 2失败 (2021终止) NCT03413319 Bristol-Myers Squibb / AbbVie 2018 抗tau抗体，未达主要终点 Zagotenemab (LY3303560) Phase 2失败 (2021终止) NCT03518073 Eli Lilly 2018 抗tau抗体，未达主要终点 Varoglutamstat (PQ912) Phase 2失败 (2024终止) NCT03919162 (VIVA-MIND) / NCT04498650 (VIVIAD) Vivoryon Therapeutics 2019 QPCT抑制剂，VIVIAD试验失败，已转向糖尿病肾病 Semorinemab Phase 2失败 (TAURIEL/LAURIET) NCT03289143 (TAURIEL) / NCT03828747 (LAURIET) Genentech / Roche 2018 TAURIEL未达终点，LAURIET部分终点阳性但功能终点阴性 Idalopirdine Phase 3失败 NCT01955143 Lundbeck / Otsuka 2015 5-HT6受体拮抗剂 Intepirdine Phase 3失败 NCT02585934 Axovant 2017 5-HT6受体拮抗剂 Bapineuzumab Phase 3失败 NCT00575055 / NCT00574132 Pfizer / Janssen 2014 抗Aβ抗体，未达临床终点 Verubecestat (MK-8931) Phase 3失败 (2017终止) NCT01739348 Merck 2017 BACE1抑制剂，因无效提前终止 Lanabecestat (AZD3293) Phase 3失败 (2018终止) NCT02245737 AstraZeneca / Eli Lilly 2018 BACE1抑制剂 Atabecestat (JNJ-54861911) Phase 3失败 (2018终止) NCT02569398 Janssen 2018 BACE1抑制剂，肝毒性 Crenezumab Phase 3失败 (2019终止/2022发表) NCT02670083 (CREAD) / NCT03114657 (CREAD2) Roche / Genentech 2019 CREAD/CREAD2试验因无效提前终止 Gantenerumab Phase 3失败 (2022.11) NCT03444870 (GRADUATE I) / NCT03443973 (GRADUATE II) Roche / Genentech 2018 GRADUATE试验未达主要终点，未能减缓认知下降 Solanezumab Phase 3失败 (2023年A4研究失败) NCT02008357 (A4 Study) Eli Lilly 2014 EXPEDITION 1/2及A4研究均未达终点 Simufilam (PTI-125) Phase 3失败 (2024-2025) NCT04994483 (RETHINK-ALZ) / NCT05026177 (REFOCUS-ALZ) Cassava Sciences 2021.11 Filamin A抑制剂，两项Phase 3均未达终点，已停止开发 Aduhelm (Aducanumab) 已退市 (FDA 2021.6加速批准, 2024.1停产) NCT02484547 (EMERGE) Biogen / Neurimmune 2021.6 2024年1月Biogen宣布停产，非安全/疗效原因

临床3期上市批准抗体药物偶联物加速审批申请上市

2026-01-02

·drugs

Study Compares Short-Term Use of Cannabinoid Products for Chronic Pain

FRIDAY, Jan. 2, 2026 -- Short-term treatment with comparable and high tetrahydrocannabinol (THC)-to- cannabidiol (CBD) ratio cannabinoid products may improve pain and increase common adverse events, according to a review published online Dec. 23 in the Annals of Internal Medicine . Roger Chou, M.D., from the Oregon Health & Science University in Portland, and colleagues conducted a systematic review to update the evidence on cannabinoids for chronic pain . Cannabinoids were classified by THC-to-CBD ratio (high, comparable, or low), source, and administration method. Cannabinoids were assessed in 25 short-term (one to six months) randomized controlled trials, with 2,303 participants. The researchers found that pain severity may be reduced slightly with oral synthetic/purified high THC-to-CBD (THC only) and oromucosal, extracted, comparable THC-to-CBD ratio products (pooled differences, −0.78 and −0.54 points, respectively); moderate-to-large increases were seen in dizziness, sedation, and nausea. Nabilone moderately reduced pain severity but dronabinol did not, among THC-only products (pooled differences, −1.59 and −0.23 points, respectively). Outcomes may not be improved by low THC-to-CBD interventions. CBD alone may not increase harms, while low THC-to-CBD mixed THC/CBD products may increase dizziness, sedation, and nausea. "CBD-based products are widely available in dispensaries. Many people use these products and they think it helps," Chou said in a statement. "Our goal is to provide some scientific basis to help people make their decisions." Abstract/Full Text (subscription or payment may be required) Editorial (subscription or payment may be required)

临床结果

2025-12-30

·Science Daily

What cannabis really does for chronic pain

Cannabis products with higher THC levels may slightly reduce chronic pain, particularly nerve pain, according to a review of multiple clinical trials. The improvement was small and short-lived, while side effects were more common. Products with little or no THC, including CBD-only formulations, showed no clear benefit. Researchers say more long-term studies are needed.A large review of medical studies examined whether cannabis-based products can help people living with chronic pain, a condition defined as pain that lasts for months or even years. The analysis included data from more than 2,300 adults and focused on products containing different amounts of two well-known cannabis compounds: tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the compound responsible for the "high" associated with marijuana, while CBD does not cause intoxication and is often marketed for wellness and pain relief. The review found that cannabis products with higher levels of THC compared to CBD may offer small, short-term improvements in pain levels and physical functioning. These modest benefits were most noticeable among people with nerve-related pain, also known as neuropathic pain, which can cause burning, tingling, or shooting sensations. However, the potential benefits came with drawbacks. Products higher in THC were also linked to a greater risk of common side effects. In contrast, products with low THC content, including CBD-only formulations, did not appear to meaningfully reduce pain. The findings were published in Annals of Internal Medicine. How the Research Was Conducted The review was led by researchers from Oregon Health & Science University working with other experts in the field. They analyzed 25 short-term, placebo-controlled randomized trials, which are considered one of the strongest types of clinical studies because they compare an active treatment to an inactive placebo. The goal was to update earlier evidence on how effective cannabis-based products are for chronic pain and how often they cause harm. To better compare results across studies, the researchers grouped cannabis products in several ways. They classified cannabinoids based on the ratio of THC to CBD (high, comparable, low). They also noted whether the products were synthetic, meaning made in a laboratory, purified, or extracted directly from a cannabis plant. In addition, they examined how the products were taken, including oral forms such as pills, oromucosal sprays applied inside the mouth, and topical products applied to the skin. The team then measured changes in pain severity, physical function, and the occurrence of adverse events. What the Results Showed The data suggested that oral products containing only THC likely led to a slight reduction in pain severity. Among these, nabilone showed a moderate benefit, while dronabinol produced little or no meaningful improvement. Nabiximols, a product that contains both THC and CBD, slightly reduced pain but did not improve physical function, which includes activities such as walking, working, or completing daily tasks. Across the studies, products with high or comparable THC levels were consistently associated with higher rates of side effects. These adverse events included dizziness, sedation, and nausea, with increases described as moderate to large. Because most of the trials were short in duration, the authors emphasized that there is still limited information about long-term safety and effectiveness. They also noted that many types of cannabis products commonly used by the public have not yet been well studied. Expert Perspective and What Comes Next An accompanying editorial from the UCLA Center for Cannabis and Cannabinoids explains that the findings highlight both the potential and the limitations of cannabinoids for treating chronic pain. The editorial notes that while THC-based products may provide modest relief for some patients, the results across studies were inconsistent and safety concerns remain. The authors of the editorial stress that more high-quality research is needed to better understand long-term outcomes and to help guide decisions made by patients, clinicians, and policymakers. Until stronger evidence is available, the role of cannabis-based products in chronic pain treatment remains limited and uncertain.

临床结果

100 项与大麻隆相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05099	大麻隆	A04AD11	DB00486

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
化疗引起的恶心和呕吐	美国	Bausch Health US LLC	1985-12-26

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
躁动	临床3期	加拿大	Alzheimers Drug Discovery Foundation	2021-02-01
阿尔茨海默症	临床3期	加拿大	Alzheimers Drug Discovery Foundation	2021-02-01
原发性进行性失语	临床2期	加拿大	Douglas Mental Health University Institute	2023-03-07
原发性进行性失语	临床2期	加拿大	Alzheimers Drug Discovery Foundation	2023-03-07
额颞痴呆	临床2期	加拿大	Alzheimers Drug Discovery Foundation	2023-03-07
额颞痴呆	临床2期	加拿大	Douglas Mental Health University Institute	2023-03-07
神经痛	临床2期	加拿大	Valeant Canada Ltd.	2009-01-01
幻肢	临床2期	加拿大	Valeant Canada Ltd.	2009-01-01
肌肉痉挛	临床2期	加拿大	Valeant Canada Ltd.	2007-07-01
脊髓损伤	临床2期	加拿大	Valeant Canada Ltd.	2007-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04801641 (CTgov)	临床2期	肥胖	18	Placebo (Placebo)	築選範範鬱願鑰膚襯願 = 衊繭艱膚夢艱鏇鹽築膚簾構淵積選廠蓋鑰蓋衊 (淵餘觸淵窪願鏇膚獵壓, 製觸廠憲夢憲鏇積鹹築 ~ 鏇膚衊襯膚繭構夢憲簾) 更多	-	2026-04-09
				Nabilone (Low-Dose Nabilone)	築選範範鬱願鑰膚襯願 = 壓築選壓鑰製鹹淵選繭簾構淵積選廠蓋鑰蓋衊 (淵餘觸淵窪願鏇膚獵壓, 鹽製繭襯蓋鏇構鬱鏇醖 ~ 願壓廠觸築簾窪膚積願) 更多
NCT05180968 (DISCO-POT, ASN2024)	临床2期	尿毒症瘙痒	14	Nabilone	鬱鬱鬱憲壓壓獵衊蓋顧(齋築選淵壓簾壓膚獵獵): Difference = 4.79 (95.0% CI, -3.95 ~ 13.5), P-Value = 0.28 更多	不佳	2024-10-24
				Placebo
NCT03769896 (NMS-Nab, CTgov)	临床2期	帕金森病	48	Nabilone 0.25 mg (Treatment Group)	觸遞構範膚遞鹽選鹽淵(簾製製觸獵鹹憲鏇鑰獵) = 鑰衊獵網網繭築膚範網壓獵襯廠製鏇憲餘簾積 (窪鹽鏇簾齋簾壓網窪醖, 觸憲襯鑰構醖鏇鏇選鏇 ~ 積遞衊構廠鹹選襯窪齋) 更多	-	2021-03-02
				Placebo (Placebo Group)	觸遞構範膚遞鹽選鹽淵(簾製製觸獵鹹憲鏇鑰獵) = 鏇餘窪糧夢憲顧鹹顧壓壓獵襯廠製鏇憲餘簾積 (窪鹽鏇簾齋簾壓網窪醖, 廠構獵築範鏇淵顧鹹衊 ~ 獵繭餘獵膚鑰獵醖蓋構) 更多
NCT03773796 (NMS-Nab2, CTgov)	临床3期	帕金森病	22	Nabilone 0.25 mg	製觸憲廠蓋獵繭觸築製 = 鹹窪鬱獵鏇選憲網憲積選膚積廠範願遞製衊夢 (壓製壓襯鏇築壓觸觸憲, 衊衊蓋鑰鹹糧襯願鹽遞 ~ 襯蓋製糧構膚遞網遞選) 更多	-	2021-03-02
NCT03251326 (CTgov)	临床1/2期	创伤后应激障碍 \| 大麻滥用 \| 创伤和损伤	4	Plac+Nab (Active Nab > Plac Prop > Plac Cann)	蓋廠鏇願襯膚衊膚醖鏇(鑰願憲選蓋糧淵網積艱) = 窪構壓鬱製膚蓋鑰繭窪艱築憲醖鏇範襯鹹蓋膚 (網選範網壓獵顧製鹽願, 簾廠醖積簾範遞鑰廠憲 ~ 積繭淵衊範鏇遞膚窪壓) 更多	-	2020-10-12
				Nab (Plac Nab > Act Prop > Plac Cann)	蓋廠鏇願襯膚衊膚醖鏇(鑰願憲選蓋糧淵網積艱) = 襯繭遞衊餘衊積餘膚觸艱築憲醖鏇範襯鹹蓋膚 (網選範網壓獵顧製鹽願, 餘廠簾壓顧顧觸醖艱襯 ~ 鏇繭觸願壓襯鑰醖鬱鑰) 更多
NCT03769896 (NMS-Nab, MDS2020)	临床2期	帕金森病	48	Nabilone	餘夢糧醖選齋壓蓋鹽膚(積廠遞憲簾窪壓壓襯獵) = Similar proportions of patients in each group had adverse events (placebo-group: 42%; nabilone: 32% of the group) 構網顧鹽蓋膚顧淵遞糧 (選餘遞醖膚窪觸廠鏇窪 ) 更多	积极	2020-09-12
				Placebo
NCT03769896 (Pubmed \| Ann Neurol)	临床2期	帕金森病	47	Nabilone	餘艱夢襯醖獵網獵鹽鹽(淵構遞齋壓襯鹹糧範築) = 壓夢積窪鬱繭製願鑰鏇製築壓簾顧獵簾糧餘鑰 (憲壓餘遞鹹鏇艱顧夢鬱 )	积极	2020-08-05
				Placebo	餘艱夢襯醖獵網獵鹽鹽(淵構遞齋壓襯鹹糧範築) = 齋網築艱鹹願艱積獵憲製築壓簾顧獵簾糧餘鑰 (憲壓餘遞鹹鏇艱顧夢鬱 )
NCT02802540 (WCLC2018)	临床2/3期	肺癌	47	Nabilone	鏇鹹鬱獵衊網願鏇齋鏇(鑰範願構築簾壓願網鏇) = had a significantly improvements 簾鹹襯鬱顧衊繭襯鏇繭 (選範獵築壓鏇範壓鹽願 )	-	2018-09-24
NCT02802540 (Pubmed \| Support Care Cancer)	临床2/3期	肺癌	65	Nabilone	憲願積鬱齋選鹽襯壓遞(鏇襯積廠鹹範選構繭鑰) = 窪壓淵艱餘製製憲蓋鹹簾觸夢願夢襯廠糧憲齋 (膚構遞簾艱襯繭壓齋糧 ) 更多	积极	2018-09-01
NCT01347762 (NAB CAN, CTgov)	临床2/3期	大麻滥用	84	Nabilone (Nabilone Titrated 2 mg Daily (Phase 1))	鏇簾範衊鹹繭積窪觸簾(夢獵齋廠壓選鹽窪壓鹹) = 構襯衊夢夢壓積選範選膚製範築襯選淵鏇繭夢 (淵糧鏇簾鹽膚選夢製壓, 183.0) 更多	-	2018-06-01
				Placebo (Placebo (Phase 1))	鏇簾範衊鹹繭積窪觸簾(夢獵齋廠壓選鹽窪壓鹹) = 糧獵淵製餘蓋糧膚顧膚膚製範築襯選淵鏇繭夢 (淵糧鏇簾鹽膚選夢製壓, 349.7) 更多